Keytruda: Benefits, Uses, and the Crisis of Accessibility in India

This proves a jarring contrast. In the high-tech corridors of Boston’s Longwood Medical Area, the conversation around oncology usually centers on the next breakthrough in genomic sequencing or the latest trial at the Dana-Farber Cancer Institute. But a few thousand miles away, in the bustling hubs of Recent Delhi and Mumbai, the conversation is far more desperate. There, the struggle isn’t just about the science of survival, but the sheer, brutal math of it. Recent investigations have peeled back the curtain on a crisis where life-saving immunotherapy is being traded in a burgeoning black market because the official price tag is simply an impossible wall for the average family.

At the center of this storm is Keytruda, the brand name for pembrolizumab. For those of us who track pharmaceutical policy, Keytruda isn’t just another drug. it’s a behemoth. Manufactured by the US-based pharma giant Merck & Co (MSD), it has become one of the world’s top-selling prescription drugs, generating global sales of around $25 billion. In the US, the FDA first approved it back in 2014 for advanced skin cancer, and since then, its reach has expanded to cover 22 different types of cancers, including lung, cervical, renal cell, and aggressive breast cancers, as well as melanoma and head and neck cancers.

The Science of Breaking the Brakes

To understand why the desperation in India is so acute, you have to understand what Keytruda actually does. It isn’t chemotherapy in the traditional sense—it doesn’t just attack swift-growing cells. Instead, it belongs to a class of drugs called “checkpoint inhibitors.” Essentially, cancer cells are clever; they use specific receptors to “flip a switch” that tells the body’s T cells—the primary soldiers of the immune system—to stand down. They effectively put the brakes on the immune response.

Pembrolizumab works by attaching to these PD-1 receptors on the T cells. By blocking that interaction, the drug removes the brakes, allowing the body’s own immune system to recognize and attack the cancerous cells. It’s a sophisticated piece of biological engineering, and that sophistication comes with a price that, in many parts of the world, is prohibitive. In India, a single 100 mg vial can cost over Rs 1.5 lakh, a figure that locks out thousands of patients who are staring down a diagnosis with no financial safety net.

The Peril of the Parallel Market

When the gap between a patient’s need and their ability to pay becomes this wide, a void is created, and the black market is always happy to fill it. The investigation by The Indian Express and the International Consortium of Investigative Journalists (ICIJ) has unearthed a disturbing trend: a counterfeit supply chain for Keytruda. Because the official market price is out of reach, families are turning to unauthorized sources, often lured by lower prices.

The reality is terrifying. These aren’t just “generic” versions; they are often counterfeits that raise massive safety concerns. Even more alarming is the discovery of hospital-level breaches. Police investigators have found evidence linking actual hospital staff to these counterfeit supplies, suggesting that the very institutions meant to provide care are sometimes the conduits for these dangerous alternatives. This is the inevitable result of a system where access is constrained by cost and dosing remains standardized and high, further inflating the expense for the patient.

For those of us monitoring drug pricing trends in the US, this serves as a grim reminder of how patent protection, while designed to incentivize innovation, can create lethal barriers to access in emerging markets. Merck & Co has utilized patents to maintain these high prices, but the clock is ticking.

The Looming Patent Cliff

There is a light at the end of the tunnel, but it’s several years away. Patents for Keytruda are expected to expire between 2028 and 2030. This creates what the industry calls a “patent cliff.” Once those protections vanish, the door opens for biosimilars—the biologic equivalent of generic drugs. Indian pharmaceutical powerhouses like Biocon, Dr. Reddy’s Laboratories, and Cipla are already building their pipelines to enter this segment.

The economic scale here is staggering. Experts suggest a biosimilar opportunity of $10–15 billion. While the impact on Merck’s revenue will likely be gradual rather than a sharp drop, the entry of biosimilars could fundamentally change the accessibility of immunotherapy in India. Until then, however, patients remain trapped between an unaffordable official price and the lethal gamble of the black market.

Even here in Boston, while the specific “black market” dynamics differ, the struggle to navigate patient advocacy resources for high-cost biologics is a constant battle. Whether it’s in a clinic in Delhi or a hospital in Massachusetts, the friction between pharmaceutical profit and patient survival remains the central conflict of modern oncology.

Navigating High-Cost Oncology Care in Boston

Given my experience covering the intersection of policy and healthcare, I know that when these global pricing trends hit home, the paperwork can be as overwhelming as the diagnosis. If you or a loved one in the Boston area are struggling with the costs of immunotherapy or similar high-value biologics, you cannot do this alone. You need a specific team of specialists to fight the insurance companies and discover funding.

If you’re facing these hurdles, here are the three types of local professionals Consider be looking for:

Certified Patient Navigators

Do not confuse these with general social workers. You need navigators who specialize specifically in oncology. Look for professionals who have a proven track record of securing “Prior Authorizations” and who have direct experience with pharmaceutical company “Patient Assistance Programs” (PAPs). They should be able to tell you exactly which forms are required to trigger a manufacturer’s grant for high-cost drugs.

Oncology-Specialized Medical Billing Advocates

Biologic billing is a nightmare of codes and denials. Look for independent billing advocates who specialize in “biologic reimbursement.” You want someone who knows how to audit a hospital bill for “standardized dosing” errors and who can file sophisticated appeals based on medical necessity to force insurance coverage for drugs like pembrolizumab.

Clinical Trial Coordinators

When the drug is unaffordable and the insurance denies it, clinical trials are often the only remaining path. Seek out coordinators affiliated with major academic medical centers. The key criterion here is their ability to match your specific cancer biomarkers with active trials that provide the drug at no cost to the patient.

Ready to find trusted professionals? Browse our complete directory of top-rated healthcare specialists in the boston area today.